160 related articles for article (PubMed ID: 35668164)
1. A diastereoselective three-component reaction for the assembly of succinimide and isatin hybrid molecules with potent anticancer activities.
Yuan H; Guo Y; Zhang Z; Sha H; He Y; Xu X; Hu W
Mol Divers; 2023 Apr; 27(2):837-843. PubMed ID: 35668164
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
3. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
4. Fe3O4 Nanoparticles Mediated Synthesis of Novel Isatin-dihydropyrimidinone Hybrid Molecules as Antioxidant and Cytotoxic Agents.
Maddela S; Makula A; Jayarambabu N
Anticancer Agents Med Chem; 2017; 17(3):456-463. PubMed ID: 27173964
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties.
Zebbiche Z; Tekin S; Küçükbay H; Yüksel F; Boumoud B
Arch Pharm (Weinheim); 2021 May; 354(5):e2000377. PubMed ID: 33368627
[TBL] [Abstract][Full Text] [Related]
6. Diastereoselective aldol-type interception of phenolic oxonium ylides for the direct assembly of 2,2-disubstituted dihydrobenzofurans.
Hong K; Yang X; Zhang Z; Xie X; Lv X; Xu X; Hu W
Org Biomol Chem; 2022 Jun; 20(22):4635-4639. PubMed ID: 35611674
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel isatin-based derivatives targeting cell cycle checkpoint pathways as potential anticancer agents.
Yousef MA; Ali AM; El-Sayed WM; Qayed WS; Farag HHA; Aboul-Fadl T
Bioorg Chem; 2020 Dec; 105():104366. PubMed ID: 33212312
[TBL] [Abstract][Full Text] [Related]
9.
Adibi H; Beyhaghi E; Hayati S; Hosseinzadeh L; Amin N
Anticancer Agents Med Chem; 2022; 22(13):2439-2447. PubMed ID: 35043767
[TBL] [Abstract][Full Text] [Related]
10. Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies.
Singh H; Singh JV; Gupta MK; Saxena AK; Sharma S; Nepali K; Bedi PMS
Bioorg Med Chem Lett; 2017 Sep; 27(17):3974-3979. PubMed ID: 28797799
[TBL] [Abstract][Full Text] [Related]
11. Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents.
Ibrahim HS; Abou-Seri SM; Ismail NSM; Elaasser MM; Aly MH; Abdel-Aziz HA
Eur J Med Chem; 2016 Jan; 108():415-422. PubMed ID: 26706352
[TBL] [Abstract][Full Text] [Related]
12. Isatin derivatives with activity against apoptosis-resistant cancer cells.
Evdokimov NM; Magedov IV; McBrayer D; Kornienko A
Bioorg Med Chem Lett; 2016 Mar; 26(6):1558-1560. PubMed ID: 26883150
[TBL] [Abstract][Full Text] [Related]
13. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review on Cytotoxic and Anticancer Potential of N-Substituted Isatins as Novel Class of Compounds Useful in Multidrug-Resistant Cancer Therapy: In Silico and In Vitro Analysis.
Gupta AK; Tulsyan S; Bharadwaj M; Mehrotra R
Top Curr Chem (Cham); 2019 May; 377(3):15. PubMed ID: 31073777
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents.
Ke S; Shi L; Yang Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4628-31. PubMed ID: 26320625
[TBL] [Abstract][Full Text] [Related]
16. Artemisinin-isatin hybrids tethered via ethylene linker and their anti-lung cancer activity.
Wang R; Zhang Q; Chen M
Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200563. PubMed ID: 36572639
[TBL] [Abstract][Full Text] [Related]
17. The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds.
Guo H; Diao QP
Curr Top Med Chem; 2020; 20(16):1499-1503. PubMed ID: 32156238
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in isatin hybrids as potential anticancer agents.
Ding Z; Zhou M; Zeng C
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900367. PubMed ID: 31960987
[TBL] [Abstract][Full Text] [Related]
19. Isatin-azole hybrids and their anticancer activities.
Hou Y; Shang C; Wang H; Yun J
Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900272. PubMed ID: 31691360
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.
Wang J; Yun D; Yao J; Fu W; Huang F; Chen L; Wei T; Yu C; Xu H; Zhou X; Huang Y; Wu J; Qiu P; Li W
Eur J Med Chem; 2018 Jan; 144():493-503. PubMed ID: 29288946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
